SOUTH SAN FRANCISCO, Calif. — Pliant Therapeutics, Inc. (Nasdaq: PLRX) announced 12-week interim data from the 320 mg dose group of INTEGRIS-PSC, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis. The 320 mg...
Latest News
Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll children with high grade glioma and ependymoma HOUSTON, Texas — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system...
HOUSTON, TX — Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Rhenium (186Re) Obisbemeda for the treatment of leptomeningeal metastases (LM) in...
Cambridge, England – Scientists have developed a technique to rapidly and reliably detect genetic changes in malaria parasites in Ghana, using just a gaming laptop and portable MinION sequencer from Oxford Nanopore. Researchers from the Wellcome Sanger Institute and University of Ghana were able to demonstrate for the first time...
Pohang, South Korea – A research team consisting of Professor Kyoung-Duck Park and PhD candidates Taeyoung Moon and Huitae Joo, from the Department of Physics at Pohang University of Science and Technology (POSTECH) has engineered “broadband nanogap gold spectroscopic sensor” using a flexible material capable of bending to create a...
Poland will spend over PLN 700 million (EUR 154.8 million) in 2021-2023 to cure rare diseases as a part of the Rare Disease Plan, the health minister has announced on Monday. Currently, the Plan defines 40 specific tasks and deadlines for their implementation, worth over PLN 90 million (EUR 19.8...
AMSTERDAM, the Netherlands – Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now available to patients in the United States. Tyruko® is the first and only FDA-approved biosimilar of natalizumab for the treatment of relapsing forms of multiple sclerosis (MS), and...
Gdańsk, Poland – PolTREG S.A. (Warsaw Stock Exchange: PTG) , a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases, today announces it has published data in International Immunopharmacology which suggest that PD-1+ T-cells are a dependable biomarker for efficacy in pediatric early-onset Type-1 diabetes (T1D) patients,...
Gdańsk, Poland – PolTREG S.A., a clinical-stage biotechnology company in Europe developing cell therapies for use in a wide range of autoimmune diseases, announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO), covering the manufacturing of T-regulatory cells (T-reg) to treat Type-1 diabetes...
Ottawa, Canada – A new review in CMAJ (Canadian Medical Association Journal) is aimed at helping clinicians diagnose and manage polycystic ovarian syndrome (PCOS), an endocrine disorder that affects about 10% of females. This disorder affects females of reproductive age and is associated with infertility, miscarriage and pregnancy complications. Its...